Form 4: Bioventus Director William Hawkins Reports RSU Activity

Director William Hawkins acquired 39,789 shares of Bioventus Class A common stock via RSU vesting and received a new grant of 30,994 RSUs.

Summary

• Director William Hawkins exercised and vested 39,789 Restricted Stock Units (RSUs) into Class A common stock on June 2, 2026.
• Following the transaction, the director holds 297,640 shares of Class A common stock.
• On June 3, 2026, the director was granted an additional 30,994 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation and equity maintenance.

Positives

• Director maintains a significant equity stake of 297,640 shares, aligning interests with shareholders.

Negatives

• None identified.

Risks

• Vesting of new RSU grants is contingent upon the director continuing service on the Board of Directors through the vesting date.

Future Outlook

The newly granted 30,994 RSUs are scheduled to vest on the earlier of the day before the next Annual Meeting of Stockholders or the first anniversary of the grant date, provided the director remains in service.

Industry Context

StockSavvy.ai notes that routine RSU vesting and annual equity grants for board members are standard corporate governance practices in the medical device sector, reflecting typical director compensation structures.

Comparison to Industry Standards

• The equity-based compensation structure is consistent with standard practices for publicly traded medical technology companies.
• Director ownership levels are typical for mid-cap healthcare firms.

Stakeholder Impact

• Shareholders may view the director's continued equity retention as a sign of confidence in the company's long-term direction.

Next Steps

• Vesting of the 30,994 RSUs granted on June 3, 2026, subject to continued board service.

Key Dates

Keywords

Bioventus, BVS, Form 4, Insider Trading, Restricted Stock Units, Director Compensation